Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | GENERAL COUNSEL & CORP SEC | October 02, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date October 02, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,598 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 627 · Balance 20,598 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 2, 2026 21:37 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 627 | $26.33 | $16,508.91 |
DisclosureSEC source: 0001966716-26-000014 · form4-10022026_091025.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,598 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 00:27 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 145 | $32.47 | $4,707.87 |
DisclosureSEC source: 0001966716-26-000012 · form4-08192026_120818.xml · nonDerivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,225 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 00:27 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,716 | $32.01 | $86,931.56 |
DisclosureSEC source: 0001966716-26-000012 · form4-08192026_120818.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,370 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| August 14, 2026 Filed Aug 19, 2026 00:27 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionPerformance Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000012 · form4-08192026_120818.xml · derivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2026-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| August 14, 2026 Filed Aug 19, 2026 00:27 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000012 · form4-08192026_120818.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,457 | $29.95 | $43,637.15 |
DisclosureSEC source: 0001966716-26-000010 · form4-06182026_080652.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,086 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 601 | $34.41 | $20,679.15 |
DisclosureSEC source: 0001966716-26-000008 · form4-03242026_080316.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,543 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.34 to $35.12 per share, inclusive. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 8,692 | $33.64 | $292,358.90 |
DisclosureSEC source: 0001966716-26-000008 · form4-03242026_080316.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,144 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.28 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 21:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 72 | $32.85 | $2,365.20 |
DisclosureSEC source: 0001966716-26-000006 · form4-03192026_090304.xml · nonDerivative · entry 5 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,836 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 21:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 334 | $31.79 | $10,617.46 |
DisclosureSEC source: 0001966716-26-000006 · form4-03192026_090304.xml · nonDerivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,908 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 21:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 4,222 | $31.28 | $132,080.20 |
DisclosureSEC source: 0001966716-26-000006 · form4-03192026_090304.xml · nonDerivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,242 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 21:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,791 | $33.38 | $59,775.34 |
DisclosureSEC source: 0001966716-26-000006 · form4-03192026_090304.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,464 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 21:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,476 | $32.74 | $81,062.75 |
DisclosureSEC source: 0001966716-26-000006 · form4-03192026_090304.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,255 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000004 · form4-03172026_090341.xml · derivative · entry 6 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 12,000 shares Expires 2029-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000004 · form4-03172026_090341.xml · derivative · entry 5 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 6,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 7,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000004 · form4-03172026_090341.xml · derivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,475 Underlying: Common Stock · 7,475 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000004 · form4-03172026_090341.xml · nonDerivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000004 · form4-03172026_090341.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 7,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000004 · form4-03172026_090341.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported total includes an aggregate 425 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000002 · form4-02192026_090202.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001966716-26-000002 · form4-02192026_090202.xml · derivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,678 | $32.61 | $87,337.08 |
DisclosureSEC source: 0001966716-25-000009 · form4-12102025_091230.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,831 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.29 to $33.19 per share, inclusive. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,300 | $31.60 | $41,074.28 |
DisclosureSEC source: 0001966716-25-000009 · form4-12102025_091230.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,509 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.27 to $32.14 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:49 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,344 | $31.76 | $74,444.74 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 6 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,809 F5 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.59 to $31.97 per share, inclusive. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:49 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,437 | $31.08 | $168,997.18 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 5 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,153 F5 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share, inclusive. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:49 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,004 | $31.33 | $31,455.72 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,590 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:49 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 194 | $31.32 | $6,075.38 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,594 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:49 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 824 | $30.76 | $25,349.12 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,788 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,394 | $30.85 | $43,001.69 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 5 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,612 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 898 | $30.34 | $27,243.52 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,006 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:49 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionPerformance Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · derivative · entry 7 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F9 · derivative.exercise_date: Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:49 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 868 | $30.14 | $26,163.17 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,904 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,416 | $29.56 | $41,859.79 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,772 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 12,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · derivative · entry 6 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,357 shares Expires 2025-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F7 · derivative.exercise_date: 33,927 restricted stock units from this award vested on December 1, 2024 and 12,357 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 12,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001966716-25-000004 · form4-10072025_081001.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,800 Underlying: Common Stock · 10,000 shares Expires 2033-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F3 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award on April 15, 2023, with an additional 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $25.07 | $250,650.00 |
DisclosureSEC source: 0001966716-25-000004 · form4-10072025_081001.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,831 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $9.15 | $91,500.00 |
DisclosureSEC source: 0001966716-25-000004 · form4-10072025_081001.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:50 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 6,345 | $20.07 | $127,316.87 |
DisclosureSEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 5 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,831 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.20, inclusive. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:50 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,150 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001415889-25-023589 · form4-09032025_090917.xml · derivative · entry 7 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,801 Underlying: Common Stock · 9,150 shares Expires 2032-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:50 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 14,922 | $20.14 | $300,491.78 |
DisclosureSEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,176 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:50 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 9,150 | $7.07 | $64,690.50 |
DisclosureSEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 21:50 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 850 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001415889-25-023589 · form4-09032025_090917.xml · derivative · entry 6 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,951 Underlying: Common Stock · 850 shares Expires 2032-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 21:50 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 850 | $20.00 | $17,000.00 |
DisclosureSEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,948 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 21:50 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 850 | $7.07 | $6,009.50 |
DisclosureSEC source: 0001415889-25-023589 · form4-09032025_090917.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,683 | $18.24 | $30,694.55 |
DisclosureSEC source: 0001415889-25-022440 · form4-08202025_080802.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,948 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive. Read SEC document |
| August 14, 2025 Filed Aug 19, 2025 00:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionPerformance Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022226 · form4-08192025_120830.xml · derivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2026-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| August 14, 2025 Filed Aug 19, 2025 00:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantPerformance Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022226 · form4-08192025_120830.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2026-08-14 F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date. F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| August 14, 2025 Filed Aug 19, 2025 00:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022226 · form4-08192025_120830.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.